Carlos Leon, MD
Nephrology · St George, UTNPI 1932131869
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.
Across 206 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$672
- Amgen$642
- Travere Therapeutics, Inc.$410
- GSK$292
- OPKO Pharmaceuticals, LLC$261
- Otsuka America Pharmaceutical, Inc.$252
- plus $2K from 29 others
Across 130 payments — averaging $1901.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$110K
- AstraZeneca$43K
- Bayer$30K
- Astrazeneca UK Limited$27K
- Boehringer Ingelheim$17K
- Biogen$7K
- plus $12K from 4 others
What the payments were for
- Food & beverage$4,44895%
- Education$2125%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 31 | $672 |
| Amgen(2 entities) | 31 | $642 |
| Travere Therapeutics, Inc. | 16 | $410 |
| GSK | 13 | $292 |
| OPKO Pharmaceuticals, LLC | 13 | $261 |
| Otsuka America Pharmaceutical, Inc. | 13 | $252 |
| Calliditas Therapeutics US Inc. | 10 | $244 |
| Genentech USA, Inc. | 5 | $238 |
| Vifor Pharma, Inc. | 9 | $178 |
| Mallinckrodt Hospital Products Inc. | 9 | $176 |
| Bayer | 9 | $145 |
| Bard Peripheral Vascular, Inc. | 3 | $135 |
| Organogenesis Inc. | 1 | $118 |
| ANI Pharmaceuticals, Inc. | 4 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Ardelyx, Inc. | 4 | $70 |
| KCI USA, Inc. | 1 | $59 |
| Bioventus LLC | 1 | $58 |
| Fresenius USA Marketing, Inc. | 3 | $53 |
| Johnson & Johnson | 1 | $52 |
| Novartis | 3 | $48 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Lilly USA, LLC | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Boehringer Ingelheim | 3 | $38 |
| Shire North American Group Inc | 2 | $36 |
| Aurinia Pharma U.S., Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Cormedix Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Sanofi | 1 | $14 |
| Akebia Therapeutics Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,660 in reported general payments places this provider in the 85th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 169 | $217,605 |
| FarxigaDapagliflozin Propanediol | 80 | $70,391 |
| XphozahTenapanor Hcl | 11 | $40,189 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $22,184 |
| LinzessLinaclotide | 17 | $18,991 |
| RayaldeeCalcifediol | 13 | $15,867 |
| Sevelamer Carbonate | 38 | $12,913 |
| KerendiaFinerenone | 11 | $8,801 |
| Potassium Citrate ErPotassium Citrate | 37 | $6,159 |
| Clonidine | 17 | $2,419 |
| Tacrolimus | 23 | $1,699 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 105 | $1,440 |
| Calcitriol | 71 | $1,312 |
| Spironolactone | 63 | $993 |
| Carvedilol | 58 | $879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $38 | $217,605169 claims |
| AstraZenecaFarxiga | $672 | $70,39180 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $261 | $15,86713 claims |
| BayerKerendia | $145 | $8,80111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 74 nephrology providers in Utah.
Other nephrology in St George
- Carlos MercadoSt George$5K
- Andrew PatchettSt George$3K
- Nitpriya PaliwalSt George$1K
- Girish SinghaniaSt George$408
- Sanjiv AnandSouth Salt Lake$144K
- Alfred CheungSalt Lake City$132K
- Donald KohanSalt Lake City$119K
- Anitha VijayanMurray$118K
- Fuad ShihabSalt Lake City$83K
- William BaragerProvo$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.